La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Camden National a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Camden National..

Camden National (NASDAQ:CAC) Azioni, Catena delle Opzioni

Camden National

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

Camden National Corporation - Common Stock

Camden National Corp

Credit Acceptance Corporation - Common Stock

Credit Acceptance Corp

Legg Mason ETF Investment Trust ClearBridge All Cap Growth ESG ETF

Cache Inc

CACI International, Inc. Class A Common Stock

CACI International Inc

Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $50.25, a high estimate of $53.00, and a low estimate of $48.00. This upward trend is evident, with the current average reflecting a 6.91% increase from the previous average price target of $47.00.
<img src="https://www.benzinga.com/files/images/story/2025/1738188030_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Camden National by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Moss</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$53.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Damon Delmonte</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$50.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Steve Moss</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Damon Delmonte</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$48.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Camden National. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Camden National compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Camden National's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Camden National's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CAC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Camden National analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Camden National</h2>
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
<h3>A Deep Dive into Camden National's Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Camden National showcased positive performance, achieving a revenue growth rate of 20.05% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Camden National's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 29.97% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Camden National's ROE excels beyond industry benchmarks, reaching 2.52%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Camden National's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.23%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.7, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Where Camden National Stands With Analysts

Raymond James analyst Steve Moss reiterates Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) with a Outperform and raises the price target from $50 to $53.

News

Price Target

Reiteration

Raymond James Reiterates Outperform on Camden National, Raises Price Target to $53

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) with a Market Perform and raises the price target from $48 to $50.

Keefe, Bruyette & Woods Maintains Market Perform on Camden National, Raises Price Target to $50

Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) just disclosed its Q4 earnings on Tuesday, January 28, 2025 at 08:15 AM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Camden National beat estimated earnings by 17.0%, reporting an EPS of $1.03 versus an estimate of $0.88.
Revenue was up $8.88 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
In the previous quarter, the company beat on EPS by $0.11, resulting in a 1.0% increase change in the share price the following day.
Here's a look at Camden National's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.83</td>
<td>0.71</td>
<td>0.70</td>
<td>0.79</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.94</td>
<td>0.81</td>
<td>0.86</td>
<td>0.85</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>43.91M</td>
<td>41.72M</td>
<td>41.89M</td>
<td>42.22M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>44.99M</td>
<td>42.83M</td>
<td>41.59M</td>
<td>38.70M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Camden National <a href="https://www.benzinga.com/quote/CAC/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Earnings Breakdown: Camden National Q4

Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $0.89 by 15.73 percent. This is a 21.18 percent increase over earnings of $0.85 per share from the same period last year. The company reported quarterly sales of $47.575 million which beat the analyst consensus estimate of $45.234 million by 5.18 percent. This is a 22.95 percent increase over sales of $38.695 million the same period last year.

Earnings Beats

Camden National Q4 2024 Adj. EPS $1.03 Beats $0.89 Estimate, Sales $47.575M Beat $45.234M Estimate

<h3>Companies Reporting Before The Bell</h3>
• SAP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) is projected to report quarterly earnings at $1.51 per share on revenue of $9.14 billion. 
• NextEra Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEP#NYSE">NEP</a>) is estimated to report quarterly earnings at $0.50 per share on revenue of $368.65 million. 
• World Acceptance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRLD#NASDAQ">WRLD</a>) is expected to report quarterly earnings at $1.96 per share on revenue of $131.78 million. 
• Xerox Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>) is expected to report quarterly earnings at $0.49 per share on revenue of $1.58 billion. 
• PACCAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) is estimated to report quarterly earnings at $1.69 per share on revenue of $7.52 billion. 
• Provident Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROV#NASDAQ">PROV</a>) is likely to report quarterly earnings at $0.25 per share on revenue of $9.74 million. 
• BCB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCBP#NASDAQ">BCBP</a>) is estimated to report quarterly earnings at $0.29 per share on revenue of $24.64 million. 
• Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) is expected to report quarterly earnings at $1.50 per share on revenue of $4.87 billion. 
• JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) is estimated to report quarterly loss at $0.31 per share on revenue of $2.26 billion. 
• Sandy Spring Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SASR#NASDAQ">SASR</a>) is projected to report quarterly earnings at $0.48 per share on revenue of $104.14 million. 
• Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) is likely to report quarterly earnings at $1.49 per share on revenue of $3.77 billion. 
• Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) is projected to report quarterly earnings at $0.49 per share on revenue of $1.16 billion. 
• Sysco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) is estimated to report quarterly earnings at $0.93 per share on revenue of $20.11 billion. 
• Synchrony Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) is projected to report quarterly earnings at $1.90 per share on revenue of $3.84 billion. 
• Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) is projected to report quarterly loss at $1.69 per share on revenue of $17.10 billion. 
• Polaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) is estimated to report quarterly earnings at $0.88 per share on revenue of $1.69 billion. 
• CommVault Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) is projected to report quarterly earnings at $0.87 per share on revenue of $245.81 million. 
• RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) is likely to report quarterly earnings at $1.38 per share on revenue of $20.56 billion. 
• Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) is likely to report quarterly earnings at $0.88 per share on revenue of $45.23 million. 
• Adient (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADNT#NYSE">ADNT</a>) is expected to report quarterly earnings at $0.35 per share on revenue of $3.45 billion. 
• Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) is projected to report quarterly earnings at $6.54 per share on revenue of $18.75 billion. 
• General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) is likely to report quarterly earnings at $1.68 per share on revenue of $41.55 billion. 
• Popular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPOP#NASDAQ">BPOP</a>) is projected to report quarterly earnings at $2.11 per share on revenue of $750.00 million. 
<h3>Companies Reporting After The Bell</h3>
• Alerus Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRS#NASDAQ">ALRS</a>) is projected to report quarterly earnings at $0.28 per share on revenue of $63.09 million. 
• Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) is likely to report quarterly earnings at $2.53 per share on revenue of $2.13 billion. 
• Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) is estimated to report quarterly earnings at $3.87 per share on revenue of $6.36 billion. 
• Stride (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>) is estimated to report quarterly earnings at $1.97 per share on revenue of $569.76 million. 
• UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) is expected to report quarterly earnings at $2.26 per share on revenue of $412.27 million. 
• Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) is estimated to report quarterly earnings at $0.68 per share on revenue of $9.32 billion. 
• Trustmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMK#NASDAQ">TRMK</a>) is estimated to report quarterly earnings at $0.83 per share on revenue of $195.03 million. 
• Veritex Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBTX#NASDAQ">VBTX</a>) is projected to report quarterly earnings at $0.55 per share on revenue of $112.22 million. 
• First Commonwealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCF#NYSE">FCF</a>) is projected to report quarterly earnings at $0.35 per share on revenue of $119.92 million. 
• Merchants Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIN#NASDAQ">MBIN</a>) is estimated to report quarterly earnings at $1.30 per share on revenue of $158.80 million. 
• F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) is estimated to report quarterly earnings at $3.38 per share on revenue of $716.48 million. 
• Primis Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRST#NASDAQ">FRST</a>) is likely to report quarterly earnings at $0.11 per share on revenue of $24.78 million. 
• Houlihan Lokey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLI#NYSE">HLI</a>) is likely to report quarterly earnings at $1.49 per share on revenue of $594.64 million. 
• Hanmi Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAFC#NASDAQ">HAFC</a>) is likely to report quarterly earnings at $0.52 per share on revenue of $61.52 million. 
• Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) is likely to report quarterly earnings at $1.21 per share on revenue of $910.83 million. 
• Littelfuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFUS#NASDAQ">LFUS</a>) is estimated to report quarterly earnings at $2.04 per share on revenue of $525.10 million. 
• Ashland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) is likely to report quarterly earnings at $0.64 per share on revenue of $436.27 million. 
• NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) is estimated to report quarterly earnings at $0.59 per share on revenue of $647.78 million. 
• Renasant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNST#NYSE">RNST</a>) is projected to report quarterly earnings at $0.61 per share on revenue of $167.42 million. 
• RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) is likely to report quarterly earnings at $7.09 per share on revenue of $2.99 billion. 
• Logitech International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) is likely to report quarterly earnings at $1.34 per share on revenue of $1.24 billion. 
• First Busey (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BUSE#NASDAQ">BUSE</a>) is expected to report quarterly earnings at $0.51 per share on revenue of $116.45 million. 
• Provident Finl Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFS#NYSE">PFS</a>) is expected to report quarterly earnings at $0.50 per share on revenue of $210.60 million. 
• LendingClub (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $206.47 million. 
• Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) is likely to report quarterly earnings at $1.06 per share on revenue of $253.56 million. 
• Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) is likely to report quarterly earnings at $5.38 per share on revenue of $10.83 billion. 
• BXP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) is likely to report quarterly earnings at $1.80 per share on revenue of $796.14 million. 
• Flushing Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIC#NASDAQ">FFIC</a>) is likely to report quarterly earnings at $0.22 per share on revenue of $45.98 million. 
• Axos Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>) is expected to report quarterly earnings at $1.75 per share on revenue of $303.63 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADNT

ALRS

BCBP

BPOP

BUSE

CVLT

FFIC

FFIV

FRST

HAFC

JBLU

LFUS

LOGI

MANH

MBIN

PCAR

PROV

QRVO

RNST

SASR

SBUX

TRMK

UMBF

VBTX

WRLD

Earnings Scheduled For January 28, 2025

Camden National Corporation ("Camden National") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>), the bank holding company for Camden National Bank, announced today that it had received all necessary regulatory approvals to complete its previously announced proposed merger with Northway Financial, Inc. ("Northway") (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/NWYF#OTCQB">NWYF</a>), the parent company of Northway Bank. The transaction is expected to close on or about January 2, 2025, pending satisfaction of customary closing conditions.

NWYF

Camden National Receives Regulatory Approvals For Merger Of Northway Financial; Transaction Is Expected To Close On Or About January 2, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keefe, Bruyette &amp; Woods analyst Michael Brown upgraded the rating for Ares Management Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) from Market Perform to Outperform and raised the price target from $166 to $202. Ares Management shares closed at $171.08 on Thursday. See how other analysts view this stock.</li>
<li>Raymond James analyst Steve Moss upgraded Camden National Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) from Market Perform to Outperform and announced a $50 price target. Camden National shares closed at $42.29 on Thursday. <a href="https://www.benzinga.com/quote/CAC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods analyst Aidan Hall upgraded the rating for Evercore Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>) from Market Perform to Outperform and boosted the price target from $269 to $339. Evercore shares closed at $270.57 on Thursday. <a href="https://www.benzinga.com/quote/EVR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods analyst Aidan Hall upgraded Moelis &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) from Market Perform to Outperform and raised the price target from $71 to $86. Moelis shares closed at $71.72 on Thursday. See how other analysts view this stock.</li>
<li>Mizuho analyst Gabriel Moreen upgraded the rating for Spire Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) from Neutral to Outperform and raised the price target from $65 to $76. Spire shares closed at $65.55 on Thursday. <a href="https://www.benzinga.com/quote/SR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying EVR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="606" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20094406/image-182-1024x606.png" alt="" class="wp-image-701936" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20094406/image-182-1024x606.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20094406/image-182-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20094406/image-182-768x454.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20094406/image-182.png 1111w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Upgrades

Markets

Trading Ideas

ARES

This Evercore Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Raymond James analyst Steve Moss upgrades Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) from Market Perform to Outperform and announces $50 price target.

Raymond James Upgrades Camden National to Outperform, Announces $50 Price Target

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) with a Market Perform and raises the price target from $43 to $48.

Keefe, Bruyette & Woods Maintains Market Perform on Camden National, Raises Price Target to $48

WIIM

ABCB

ACNB

AMAL

AMTB

AROW

BANF

BANR

BCAL

BFST

BHLB

BHRB

BMRC

BOKF

BRKL

BSRR

BSVN

CARE

CASH

CATY

CBAN

CBNK

CBSH

CCBG

CCNE

CFFN

CHCO

CLBK

CNOB

COFS

CTBI

CUBI

CVBF

CZFS

DCOM

EBTC

EFSC

EGBN

EQBK

EWBC

FBIZ

FBMS

FBNC

FCBC

FCNCA

FFBC

FFIN

FFWM

FIBK

FISI

FLIC

FMAO

FMBH

FMNB

FNLC

FRBA

FRME

FSBC

GABC

GBCI

GCBC

GNTY

GSBC

HBCP

HBNC

HFBL

HFWA

HIFS

HMST

HOMB

HONE

HOPE

HTBI

HTBK

HTLF

Shares of banking-related companies are trading higher after Donald Trump won the US presidential election.

Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.83 by 13.25 percent. This is a 40.3 percent increase over earnings of $0.67 per share from the same period last year. The company reported quarterly sales of $44.99 million which beat the analyst consensus estimate of $43.91 million by 2.47 percent. This is a 19.48 percent increase over sales of $37.66 million the same period last year.

Camden National Q3 Adj $0.94 Beats $0.83 Estimate, Sales $44.99M Beat $43.91M Estimate

Investors might want to bet on Camden National (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cac#NASDAQ">CAC</a>), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
A company&#39;s changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.
The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.
Therefore, the Zacks rating upgrade for Camden National basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
<h2>Most Powerful Force Impacting Stock Prices</h2>
The change in a company&#39;s future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company&#39;s shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
For Camden National, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company&#39;s underlying business. And investors&#39; appreciation of this improving business trend should push the stock higher.
<h2>Harnessing the Power of Earnings Estimate Revisions</h2>
Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.
<h2>Earnings Estimate Revisions for Camden National</h2>
This bank is expected to earn $3.33 per share for the fiscal year ending December 2024, which represents a year-over-year change of -8.3%.
Analysts have been steadily raising their estimates for Camden National. Over the past three months, the Zacks Consensus Estimate for the company has increased 6.4%.
<h2>Bottom Line</h2>
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of &#39;buy&#39; and &#39;sell&#39; ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a &#39;Strong Buy&#39; rating and the next 15% get a &#39;Buy&#39; rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
The upgrade of Camden National to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
<a href="https://www.zacks.com/stock/news/2340062/what-makes-camden-national-cac-a-new-strong-buy-stock?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2340062">To read this article on Zacks.com click here.</a>

Small Cap

What Makes Camden National a New Strong Buy Stock

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Ascendiant Capital raised the price target for Atossa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) from $6.25 to $6.5. Ascendiant Capital analyst Edward Woo maintained a Buy rating. Atossa Therapeutics shares gained 7.4% to close at $1.46 on Tuesday. <a href="https://www.benzinga.com/quote/atos/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut the price target for Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) from $135 to $130. B of A Securities analyst Graham Perry downgraded the stock from Buy to Neutral. Novartis shares fell 0.2% to close at $116.99 on Tuesday. <a href="https://www.benzinga.com/quote/NVS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keefe, Bruyette &amp; Woods raised Camden National Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NYSE">CAC</a>) price target from $40 to $41. Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintained a Market Perform rating. Camden National shares fell 0.3% to close at $37.78 on Tuesday. <a href="https://www.benzinga.com/quote/CAC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) price target from $41 to $36. Piper Sandler analyst David Amsellem downgraded the stock from Overweight to Neutral. Supernus Pharmaceuticals shares fell 1.2% to close at $33.49 on Tuesday. <a href="https://www.benzinga.com/quote/SUPN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised the price target for AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) from $100 to $120. B of A Securities analyst Omar Dessouky maintained a Buy rating. AppLovin shares fell 0.1% to close at $86.23 on Tuesday. <a href="https://www.benzinga.com/quote/APP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel boosted Krystal Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) price target from $204 to $220. Stifel analyst Dae Gon Ha maintained a Buy rating. Krystal Biotech shares fell 1.4% to close at $185.00 on Tuesday. <a href="https://www.benzinga.com/quote/KRYS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital cut Dave &amp; Buster&#8217;s Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) price target from $65 to $55. BMO Capital analyst Andrew Strelzik maintained an Outperform rating. Dave &amp; Buster&#8217;s shares fell 0.8% to close at $29.86 on Tuesday. <a href="https://www.benzinga.com/quote/PLAY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush cut the price target for GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) from $11 to $10. Wedbush analyst Michael Pachter maintained an Underperform rating. GameStop shares fell 3.3% to close at $23.45 on Tuesday. <a href="https://www.benzinga.com/quote/GME/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities boosted Academy Sports and Outdoors, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) price target from $60 to $63. Truist Securities analyst Joseph Civello maintained a Buy rating. Academy Sports shares gained 5.2% to close at $55.38 on Tuesday. <a href="https://www.benzinga.com/quote/ASO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital cut Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) price target from $525 to $510. BMO Capital analyst Andrew Strelzik maintained an Outperform rating. Domino&#8217;s shares fell 0.8% to close at $416.77 on Tuesday. <a href="https://www.benzinga.com/quote/DPZ/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying DPZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="534" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11090617/image-87-1024x534.png" alt="" class="wp-image-542314" style="width:481px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11090617/image-87-1024x534.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11090617/image-87-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11090617/image-87-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11090617/image-87.png 1276w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Pre-Market Outlook

ATOS

KRYS

PLAY

SUPN

Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) with a Market Perform and raises the price target from $40 to $41.

Keefe, Bruyette & Woods Maintains Market Perform on Camden National, Raises Price Target to $41

Camden National Corporation To Acquire Northway Financial In All-Stock Transaction Valued At ~$86.6M; Northway Shareholders To Receive 0.83 Shares Of Camden National Common Stock For Each Outstanding Share Of Northway

Stephens &amp; Co. analyst Matt Breese maintains Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) with a Equal-Weight and raises the price target from $35 to $42.

Stephens & Co. Maintains Equal-Weight on Camden National, Raises Price Target to $42

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) with a Market Perform and raises the price target from $37 to $40.

Keefe, Bruyette & Woods Maintains Market Perform on Camden National, Raises Price Target to $40

Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $0.71 by 14.08 percent. This is a 4.71 percent decrease over earnings of $0.85 per share from the same period last year. The company reported quarterly sales of $42.829 million which beat the analyst consensus estimate of $41.718 million by 2.66 percent. This is a 0.07 percent increase over sales of $42.800 million the same period last year.

Camden National Q2 2024 Adj. EPS $0.81 Beats $0.71 Estimate, Sales $42.829M Beat $41.718M Estimate

MainStreet Bank (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnsb#NASDAQ">MNSB</a>) came out with quarterly earnings of $0.27 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.85 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -15.63%. A quarter ago, it was expected that this company would post earnings of $0.52 per share when it actually produced earnings of $0.36, delivering a surprise of -30.77%.
Over the last four quarters, the company has not been able to surpass consensus EPS estimates.
MainStreet Bank, which belongs to the Zacks Banks - Northeast industry, posted revenues of $16.16 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 1.81%. This compares to year-ago revenues of $20.08 million. The company has not been able to beat consensus revenue estimates over the last four quarters.
The sustainability of the stock&#39;s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management&#39;s commentary on the earnings call.
MainStreet Bank shares have lost about 26.7% since the beginning of the year versus the S&amp;P 500&#39;s gain of 14.5%.
What&#39;s Next for MainStreet Bank?
While MainStreet Bank has underperformed the market so far this year, the question that comes to investors&#39; minds is: what&#39;s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company&#39;s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for MainStreet Bank: mixed. While the magnitude and direction of estimate revisions could change following the company&#39;s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.36 on $17.1 million in revenues for the coming quarter and $1.32 on $67.13 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - Northeast is currently in the top 16% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Camden National (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cac#NASDAQ">CAC</a>), is yet to report results for the quarter ended June 2024. The results are expected to be released on July 30.
This bank is expected to post quarterly earnings of $0.71 per share in its upcoming report, which represents a year-over-year change of -16.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Camden National&#39;s revenues are expected to be $41.64 million, down 2.7% from the year-ago quarter.
<a href="https://www.zacks.com/stock/news/2310686/mainstreet-bank-mnsb-lags-q2-earnings-and-revenue-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-2310686">To read this article on Zacks.com click here.</a>

Earnings Misses

MNSB

MainStreet Bank Lags Q2 Earnings and Revenue Estimates

Press Releases

Camden National Corporation and Northway Financial, Inc. to Merge

Dividends

Camden National Corporation Announces its Third Quarter 2024 Dividend

Camden National Corporation to Announce Quarter Ended September 30, 2024 Financial Results on October 29, 2024

Camden National Corporation Reports Third Quarter 2024 Earnings of $13.1 Million and Diluted EPS of $0.90

Camden National Corporation Announces its Fourth Quarter 2024 Dividend

Camden National Corp. Receives Regulatory Approvals for Merger of Northway Financial, Inc.

Camden National Corp. Announces Successful Merger with Northway Financial

Camden National Corporation to Announce Quarter and Year Ended December 31, 2024 Financial Results on January 28, 2025

CAMDEN NATIONAL CORPORATION REPORTS FOURTH QUARTER AND YEAR END 2024 FINANCIAL RESULTS

Comments

Camden National

Camden National (CAC) Opzioni

Camden National (NASDAQ:CAC) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO